The University of New Mexico (UNM) Cancer Center is set to conduct a clinical trial focusing on non-surgical treatments for uterine cancer, supported by the Route 66 Specialized Program of Research Excellence (SPORE) grant. This initiative aims to provide alternative treatment options, particularly for younger women who wish to preserve their ability to bear children, and for older women who may face challenges recovering from surgery.
Hormone Therapy and Biomarker Identification
Kimberly K. Leslie, MD, principal investigator, notes that hormone therapy can reverse approximately 70% of early-stage uterine cancers. The clinical trial aims to identify biomarkers that can predict which women will respond favorably to hormone therapy, thus enabling more targeted and effective treatment strategies. Currently, clinicians lack the ability to predict treatment response, making this a critical area of investigation. The team includes gynecologic oncologists Carolyn Muller, MD, and Sarah Adams, MD, who will collect biological samples from participants, oncology pathologist Edgar Fischer, MD, PhD, and biostatistician Jianrong Wu, PhD.
Lifestyle Interventions and Treatment Outcomes
In addition to hormone therapy, the clinical trial will explore the impact of lifestyle interventions, such as intensive exercise and diet control, on uterine cancer treatment outcomes. Studies suggest that these lifestyle choices can positively influence treatment results. The trial will include a specialist to consult with enrollees on these lifestyle modifications.
Multi-Institutional Collaboration and Patient Enrollment
The UNM Cancer Center clinical trial will involve approximately 25 women, with the broader Route 66 SPORE projects encompassing over 100 women across the University of Oklahoma and Washington University. Participants will be followed for at least three years to assess the long-term efficacy of the interventions. Andrew Sussman, PhD, will address diversity issues during recruitment to ensure culturally appropriate participation of New Mexico women.
Significance of the Research
This research is supported by the National Cancer Institute of the National Institutes of Health. The trial underscores a commitment to improving uterine cancer treatment outcomes through personalized and less invasive approaches. By identifying predictive biomarkers and integrating lifestyle modifications, the study aims to enhance the quality of life and treatment success for women affected by uterine cancer.
